Skip to main content

IRB Barcelona spin-off Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

30 Sep 21




Press and Communications Officer
Tel.+34 93 40 37255
  • Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis.

  • Data published in Journal of National Cancer Institute, Cancer Spectrum.

  • MAF negative status of patients who were treated with clodronate in the adjuvant setting was predictive of significantly improved disease-free survival (primary endpoint) and overall survival (key secondary endpoint).

  • Results confirm the company’s previous data (AZURE trial analyses) on its proprietary MAF Test® published in Lancet Oncology in 2018.

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).